Modeling multi-drug chemotherapy: Tailoring treatment to individuals

Journal of Theoretical Biology

Volumn 214, Issue 2, 2002, Pages 181-207

  Gardner, Shea N ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

CANCER;

APOPTOSIS; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CELL CYCLE PHASE; CELL DIVISION; CELL KINETICS; CELL PROLIFERATION; CONVALESCENCE; DRUG COMBINATION; DRUG DOSE; DRUG RESISTANCE; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TOXICITY; MODEL; MOLECULAR EVOLUTION; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SIMULATION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 0036350193     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1006/jtbi.2001.2459     Document Type: Article

References (91)

1. Consequences of increasing resistance to antimicrobial agents
2. Amplification of cellular oncogenes in cancer cells
3. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in post-menopausal patients with advanced breast cancer - A randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group
4. Cell proliferation kinetics of normal and tumor tissue in vitro: Quiescent reproductive cells and the cycling reproductive fraction
5. Treatment-induced changes in sensitivity in a multiclonal human tumor mixture model in vitro
6. Cell proliferation in tumors
7. A mathematical model of the development of drug resistance to cancer chemotherapy
8. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes
9. Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients
10. Growth of necrotic tumors in the presence and absence of inhibitors
11. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia
12. Demography and population dynamics of the Mediterranean fruit fly
13. Anticancer drugs
14. Impact of dose-intense chemotherapy on the development of permanent drug resistance
15. Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers
16. Prediction of response to primary chemotherapy for operable breast cancer
17. Rapid administration of multiple cycles of high-dose myelo-supressive chemotherapy in patients with metastic breast cancer
18. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors: Cytokinetic e!ects on bone marrow hematopoietic progenitors
19. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy
20. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
21. Changes in biological markers after primary chemotherapy for breast cancers
22. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
23. Polychemotherapy for early breast cancer: An overview of the randomised trials
24. Proliferative rate by S-phase measurement may affect cure of breast carcinoma
25. A mechanistic, predictive model of dose response curves for cell cycle phase-specific and -non-specific drugs
26. Scheduling chemotherapy: Catch 22 between cell kill and resistance evolution
27. A revolving dose strategy to delay the evolution of both quantitative vs. major monogene resistances to pesticides and drugs
28. Breast cancer cell kinetics: Immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness
29. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
30. Quiescence as an explanation of Gompertzian tumor growth
31. The importance of drug scheduling in cancer chemotherapy: Etoposide as an example
32. The dynamics of gene amplication described as a multitype compartmental model and as a branching process
33. Cell kinetic measurements: Principles, guidelines for treatment?
34. Hypoxic cervical cancers with low apoptotic index are highly aggressive
35. An approach to a biomathematical model of lymphocytopoiesis
36. Mathematical model for human myeloma relating growth kinetics and drug resistance
37. Combination chemotherapy and adriamycin in patients with advanced breast cancer
38. Evaluation of high-dose versus standard CAF chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study
39. Average relative dose intensity and the impact on design of clinical trials
40. A less toxic regimen of 5-fuorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas
41. Endocrine pharmacology of antiestrogens as antitumor agents
42. Acute leukemia: The kinetics of leukemic blast cells in man. Ser. Haematol
43. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions
44. HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand
45. Changes in the extents of viable and necrotic tissue, interstitial fluid pressure, and proliferation kinetics in clone. A human colon tumour xenografts as a function of tumour size
46. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance
47. Apoptosis in breast cancer: Relationship with other pathological parameters
48. Appearance of amplied thymidylate synthase or dihydrofolate reductase genes in stage-IV breast-cancer patients receiving endocrine treatment
49. Biology of haemopoietic stem cell
50. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors p53, c-erB-2, MiB1, pS2 and GST
51. Analysis of growth of muticellular tumour spheroids by mathematical models
52. The kinetics of cancer cells and of HIV1: The problems of cell and virus rebounds and of latency
53. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
54. Measurements of cellular proliferation and DNA in breast carcinoma
55. Heterogeneity in the development of apoptosis in irradiated murine tumours of diffrerent histologies
56. Mathematical models for multidrug resistance and its reversal
57. Tumor heterogeneity: A review of the theory
58. Host response in tumor growth and progression
59. Cell kinetics and response to primary intra-arterial chemotherapy in patients with advanced oral cavity tumors
60. An example of the e!ects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy
61. A Gompertzian model of human breast cancer growth
62. Tumor size, sensitivity to therapy, and design of treatment schedules
63. The Norton-Simon hypothesis revisited
64. Characterization of the p53 tumor supressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
65. A mathematical model of drug resistance: Heterogeneous tumors
66. Biology of Erythropoiesis, erythroid differentiation, and maturation
67. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
68. Safer cancer chemotherapy using a kinetically-based experimental approach: Higher dose intensity with reduced toxicity
69. Gene amplification, drug resistance, and cancer
70. 5 FU infusion in advanced colorectal cancer: A comparison of three dose schedules
71. Potentials of cell kinetics in the management of patients with ovarian cancers
72. Cell proliferation in 3800 node-negative breast cancers: Consistency over time of biological and clinical information provided by 3H-thymidine labelling index
73. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer
74. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas
75. Experimental evaluation of potential anticancer agents. XXI, Scheduling or arabinosyl cytosine to take advantage of its S-phase specificity against leukemia cells
76. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
77. Will increases in dose intensity improve outcome: Con
78. A stochastic numerical model of breast cancer growth that simulates clinical data
79. Decelerating growth and human breast cancer
80. Geometry, growth rates and duration of cancer and carcinoma in situ of the breast before detection by screening
81. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery
82. Cell kinetics and chemotherapy: A critical review
83. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer
84. Are cell kinetic data relevant for the design of tumour chemotherapy schedules?
85. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
86. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue
87. Matrix metalloproteinase inhibitors: Applications in oncology